Surmodics Announced Early Clinical Use Of The Company's Pounce LP (Low Profile) Thrombectomy System
Portfolio Pulse from Benzinga Newsdesk
Surmodics has announced the early clinical use of its Pounce LP Thrombectomy System, which received FDA clearance in June 2023. The system is in limited market evaluation with a full commercial launch expected after the LME is completed.
January 22, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics' Pounce LP Thrombectomy System is in early clinical use following FDA clearance, indicating progress towards a full commercial launch.
The early clinical use of Surmodics' Pounce LP Thrombectomy System suggests a positive development for the company. FDA clearance and the move towards a full commercial launch could lead to increased investor confidence and potential revenue growth, likely resulting in a positive short-term impact on SRDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100